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A Corrigendum on
Investigation of Nrf2, AhR and ATF4 Activation in Toxicogenomic Databases
by Zgheib, E., Limonciel, A., Jiang, X., Wilmes, A., Wink, S., van de Water, B., et al. (2018). Front.
Genet. 9:429. doi: 10.3389/fgene.2018.00429
In the original article, we neglected to mention that this work was partly supported by the
EU-ToxRisk project (An Integrated European “Flagship” Program Driving Mechanism-Based
Toxicity Testing and Risk Assessment for the 21st Century) funded by the European Commission
under the Horizon 2020 programme (Grant Agreement No. 681002).
A correction has therefore been made to the Acknowledgments:
“The research leading to these results has received support from the Innovative Medicines
Initiative Joint Undertaking (IMIJU) under grant agreement number 115439, resources of
which are composed of financial contribution from the European Union’s Seventh Framework
Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. This work was
supported by the 2015 CEFIC-LRI award (AL) and partly supported by the EU-ToxRisk project
(An Integrated European “Flagship” ProgramDrivingMechanism-Based Toxicity Testing and Risk
Assessment for the 21st Century) funded by the European Commission under the Horizon 2020
programme (Grant Agreement No. 681002). This publication reflects only the author’s views and
neither the IMI JU nor EFPIA nor the European Commission are liable for any use that may be
made of the information contained therein.”
The authors apologize for this error and state that this does not change the scientific conclusions
of the article in any way. The original article has been updated.
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